Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Synaptogenix Inc. is currently managing 2 pending office actions in the Biotechnology & Pharmaceuticals technology area. These actions are distributed across 2 distinct examiners and 2 distinct art units, indicating a diversified prosecution landscape. The distribution of matters across multiple art units suggests that the company's research and development efforts may cover different specialized areas within the biotech and pharmaceutical sectors.
The busiest examiner for the portfolio is KOSAR, ANDREW D, who is responsible for 1 busiest examiner pending action. The total of 2 pending office actions is shared between 2 distinct examiners, showing that the workload is distributed rather than centralized. For practitioners, this distribution means that prosecution strategies must be adapted to the specific expectations of different examiners across 2 distinct art units. The lack of concentration under a particular examiner requires a more varied approach to responding to office actions and managing the overall patent strategy for the company.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Double-patenting + other | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| BARSKY, JARED | 1 | 50.2% | +22.7% |
| KOSAR, ANDREW D | 1 | 42.0% | +31.8% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18547252 | TREATMENT OF OPTIC NERVE INFLAMMATION USING PKC ACTIVATORS | KOSAR, ANDREW D | 104d overdue |
| 18547266 | TREATMENT OF MULTIPLE SCLEROSIS USING PKC ACTIVATORS | BARSKY, JARED | — |
| Art Unit | Apps |
|---|---|
| 1628 | 1 |
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18547266 | TREATMENT OF MULTIPLE SCLEROSIS USING PKC ACTIVATORS | BARSKY, JARED | 1628 | §102§103DP | Non-Final OA | — | Pending | Aug 21, 2023 |
| 18547252 | TREATMENT OF OPTIC NERVE INFLAMMATION USING PKC ACTIVATORS | KOSAR, ANDREW D | 1625 | §103 | Final Rejection | 104d overdue | Pending | Aug 21, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial